About Monika Rogozinska
Professional Profile
With 25 years of executive leadership experience, Ms. Monika Rogozinska specializes in portfolio, program, project, and clinical trial management across the biotechnology, pharmaceutical, MedTech, and diagnostics sectors. Her work has driven the development of global strategies, delivered breakthrough therapies and diagnostics, and advanced meaningful healthcare innovations.
Ms. Rogozinska has led pivotal initiatives throughout her career, including developing global product strategies, optimizing R&D pipelines, managing complex clinical trials, and ensuring successful product launches. Key accomplishments include overseeing the international development and launch readiness of Bavencio® for Merck KGaA and providing transformational leadership as Chief Development Officer at Adial Pharmaceuticals, where she built operations from the ground up and implemented strategic plans, achieving measurable milestones.
At Blackmon Technologies, Ms. Rogozinska helps life science startups refine their strategies, provides regulatory and development advisory services, and establishes scalable frameworks to meet market needs. She also advises venture capital and private equity firms, offering industry insights to optimize risk capital strategies and foster transformational growth.
A passionate advocate for the next generation of leaders, Ms. Rogozinska mentors and advises through programs such as MIT Solve and the Harvard Business School New Venture Competition. These efforts and her operational and strategic expertise reflect her commitment to fostering innovation, driving growth, and shaping advancements in the life sciences sector.
Industry Experience
Monika has worked for a variety of companies in the pharmaceutical and biotechnology industries, ranging from large Fortune 500 corporations to small startups. Her extensive experience has provided her with a unique perspective on the dynamic and transformative nature of this field. Monika is enthusiastic about sharing her knowledge and experience with you, inviting you to explore the diverse tapestry of this ever-evolving landscape alongside her.
Advisory Boards Service
Advisory for Startup Accelerators
Monika is a passionate advisor to startups, and has been fortunate to work with two innovative accelerators: Creatella Impact and ReachBack.
Creatella Impact (NYC, Singapore)
Creatella Impact is a non-profit accelerator that provides early-stage social enterprises with the resources and support they need to scale their impact. Monika has been an advisor to Creatella Impact for the past three years, working closely with some amazing entrepreneurs who are dedicated to solving some of the world's most pressing problems.
ReachBack (Atlanta)
ReachBack Inc, is an entrepreneurial, experiential learning pre-seed accelerator that provides business and professional training. Monika has been an advisor to ReachBack Inc for the past two years, collaborating with exceptional entrepreneurs who are dedicated to building successful businesses
Education and Interests
Monika is a dynamic professional who combines expertise in science with a deep understanding of business and innovation. With a Master's degree in Laboratory Medicine from Nicolaus Copernicus University in Poland, Monika possesses a strong scientific foundation. She further enhanced her skills through the General Management Program (GMP) at Harvard Business School, an extensive executive program that granted her alumni status, connecting her to a global network of accomplished professionals.
Monika's commitment to continuous learning is exemplified by completing prestigious programs that have broadened her expertise across different areas. She successfully completed the Advanced Certificate for Executives in Management, Innovation, and Technology (ACE) at MIT, another comprehensive program that provided her with a deeper understanding of management, innovation, and technology. This program also conferred upon her alumni status, allowing her to tap into a vast network of innovators and thought leaders.
Building upon her foundation in science and business, Monika pursued specialized programs to expand her skill set. She completed the Venture Capital and Private Equity program at Harvard Business School, followed by the Early Startup Investments program at Columbia University, focusing on angel investing and early-stage startups. Additionally, Monika honed her expertise in mergers and acquisitions through the M&A program at Columbia University. To complement her strategic abilities, she also completed the Sales program at Kellogg School of Management, equipping her with the necessary skills to excel in sales and drive business growth.
Her interdisciplinary knowledge spans diverse areas, including blockchain, digital business strategy, and data monetization, positioning her at the forefront of innovation. Monika excels in bridging the gap between science and business, envisioning and implementing cutting-edge solutions.
Discover more about Monika's expertise and how she can contribute to your organization's success by visiting her LinkedIn page.
In the News
Adial Pharmaceuticals (NASDAQ: ADIL): Achievements and Milestones
Press release, Jan 9, 2020
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial.
Press release, Sep 25, 2019
Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019.
Press release, Nov 14, 2018
Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018.
Press release, Aug 15, 2018
Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development.